Seattle Genetics (SGEN) PT Raised to $210 at Oppenheimer on Positive Ph2 Tisotumab Vedotin (TV) Study
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Seattle Genetics (NASDAQ: SGEN) to $210.00 (from $200.00) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
